Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Y-mAbs Therapeutics Inc.

    NASDAQ: YMAB · Real-Time Price · USD
    4.87
    -0.07 (-1.42%)
    At close: Jun 17, 2025, 3:18 PM

    Y-mAbs Therapeutics Statistics

    Share Statistics

    Y-mAbs Therapeutics has 45.3M shares outstanding. The number of shares has increased by 3.04% in one year.

    Shares Outstanding

    n/a
    		 45.3M

    Shares Change (YoY)

    n/a
    		 3.04%

    Shares Change (QoQ)

    n/a
    		 0.96%

    Owned by Institutions (%)

    n/a
    		 64.53%

    Shares Floating

    n/a
    		 34.02M

    Failed to Deliver (FTD) Shares

    n/a
    		 639

    FTD / Avg. Volume

    n/a
    		 0.26%

    Short Selling Information

    The latest short interest is 2.69M, so 5.94% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 2.69M

    Short % of Shares Out

    n/a
    		 5.94%

    Short % of Float

    n/a
    		 7.04%

    Short Ratio (days to cover)

    n/a
    		 12.98

    Valuation Ratios

    The PE ratio is -11.7 and the forward PE ratio is -4.46. Y-mAbs Therapeutics's PEG ratio is -0.32.

    PE Ratio

    n/a
    		 -11.7

    Forward PE

    n/a
    		 -4.46

    PS Ratio

    n/a
    		 3.96

    Forward PS

    n/a
    		 1.2

    PB Ratio

    n/a
    		 3.77

    P/FCF Ratio

    n/a
    		 -22.09

    PEG Ratio

    n/a
    		 -0.32
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Y-mAbs Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 4.16

    Quick Ratio

    n/a
    		 3.85

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 -0.03

    Debt / FCF

    n/a
    		 -0.05

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $843,125

    Profits Per Employee

    n/a
    		 $-285,250

    Employee Count

    n/a
    		 104

    Asset Turnover

    n/a
    		 0.73

    Inventory Turnover

    n/a
    		 2.11

    Taxes

    Income Tax

    n/a
    		 -146K

    Effective Tax Rate

    n/a
    		 0.49%

    Stock Price Statistics

    The stock price has increased by -58.21% in the last 52 weeks. The beta is 0.51, so Y-mAbs Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.51

    52-Week Price Change

    n/a
    		 -58.21%

    50-Day Moving Average

    n/a
    		 4.44

    200-Day Moving Average

    n/a
    		 8.39

    Relative Strength Index (RSI)

    n/a
    		 56.63

    Average Volume (20 Days)

    n/a
    		 247,931

    Income Statement

    In the last 12 months, Y-mAbs Therapeutics had revenue of 87.69M and earned -29.67M in profits. Earnings per share was -0.67.

    Revenue

    n/a
    		 87.69M

    Gross Profit

    n/a
    		 72.43M

    Operating Income

    n/a
    		 -31.2M

    Net Income

    n/a
    		 -29.67M

    EBITDA

    n/a
    		 -30.67M

    EBIT

    n/a
    		 -31.2M

    Earnings Per Share (EPS)

    n/a
    		 -0.67
    Full Income Statement

    Balance Sheet

    The company has 67.23M in cash and 820K in debt, giving a net cash position of 66.41M.

    Cash & Cash Equivalents

    n/a
    		 67.23M

    Total Debt

    n/a
    		 820K

    Net Cash

    n/a
    		 66.41M

    Retained Earnings

    n/a
    		 -487.14M

    Total Assets

    n/a
    		 112.61M

    Working Capital

    n/a
    		 71.49M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -15.71M and capital expenditures 0, giving a free cash flow of -15.71M.

    Operating Cash Flow

    n/a
    		 -15.71M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -15.71M

    FCF Per Share

    n/a
    		 -0.35
    Full Cash Flow Statement

    Margins

    Gross margin is 82.61%, with operating and profit margins of -35.58% and -33.83%.

    Gross Margin

    n/a
    		 82.61%

    Operating Margin

    n/a
    		 -35.58%

    Pretax Margin

    n/a
    		 -34%

    Profit Margin

    n/a
    		 -33.83%

    EBITDA Margin

    n/a
    		 -34.97%

    EBIT Margin

    n/a
    		 -35.58%

    FCF Margin

    n/a
    		 -17.92%

    Dividends & Yields

    YMAB does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for YMAB is $17, which is 246.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $17

    Price Target Difference

    n/a
    		 246.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 11
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 0.1

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist